Abstract 139P
Background
The management of anal squamous cell carcinoma (ASCC) has yet to benefit from the progress of precision medicine. The few prognostic factors assessed to date are insufficient to accurately predict clinical outcomes. Patients with tumor resistant to chemoradiation therapy, or those experiencing localized recurrence after treatment, are subject to abdominoperineal resection (APR), an invasive procedure that significantly impairs quality of life. Genomic analyses could identify new prognostic biomarkers and potential avenues for targeted therapies.
Methods
We assessed the prognostic and theragnostic value of pathogenic variants identified in 571 cancer-related genes in surgical samples collected from a multicentric retrospective French cohort of 158 ASCC patients who underwent APR.
Results
Alterations in PI3K/AKT/mTOR (43%), chromatin remodeling (48%), and Notch pathways (22%) were frequent in HPV-positive tumors, while HPV-negative tumors (11%) often had variants in cell cycle regulation and genome integrity maintenance genes, like TP53 (59%) and TERT promoter mutations (47%). In patients with HPV-positive tumors, KMT2C (16%) and PIK3CA exon 9/20 pathogenic variants (22%) were associated with poor overall survival (Hazard Ratio (HR)KMT2C = 2.54, 95%CI = 1.25-5.17, p-value = 0.010; HRPIK3CA = 2.43, 95%CI = 1.3-4.56, p-value = 0.006), and progression-free survival (HRKMT2C = 3.38, 95%CI = 1.83-6.26, p-value < 0.001; HRPIK3CA = 1.81, 95%CI = 1.06-3.08, p-value = 0.029) in multivariate analyses. Alterations with theragnostic value in another cancer type (e.g., PIK3CAH1047R or loss-of-function variants in homologous repair genes) were detected in 43% of tumors.
Conclusions
PIK3CA exon 9/20 and KMT2C pathogenic variants are independent prognostic factors in patients with HPV-positive ASCC treated by APR. Importantly, the high prevalence of alterations with potential theragnostic value strongly supports the use of genomic profiling to allow patient enrollment in precision medicine clinical trials.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Fondation de France, Société Nationale Française de Gastroentérologie, Ligue Contre le Cancer.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
169P - A real-world molecular pre-screening program in advanced breast cancer (ABC) at Institut Català d'Oncologia l'Hospitalet: Clinical practice study to assess treatment-decision choice based on molecular results
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
170P - KRAS status in patients with pancreatic ductal adenocarcinoma: A single-center study from 2020 to 2023
Presenter: Manukyan Mariam
Session: Cocktail & Poster Display session
Resources:
Abstract
171P - Benefit of next-generation sequencing for lung cancer patients in a limited-resource area
Presenter: Kijjakom Thanasombunsukh
Session: Cocktail & Poster Display session
Resources:
Abstract
172P - Survival prediction using CT based radiomic features in patients of pancreatic cancer treated by chemotherapy followed by SBRT: A pilot study
Presenter: Divya Khosla
Session: Cocktail & Poster Display session
Resources:
Abstract
173P - Overcoming monocyte imbalance and T cell exhaustion in obesity-associated colorectal cancer liver metastasis
Presenter: Alyssa Cristea
Session: Cocktail & Poster Display session
Resources:
Abstract
174TiP - A pivotal clinical trial of a functional ex vivo organ culture assay for cancer precision medicine
Presenter: Sandra Hanks
Session: Cocktail & Poster Display session
Resources:
Abstract
177TiP - Myeloid-derived suppressor cells in the peripheral blood of patients with colorectal cancer: A trial in progress
Presenter: Hans Raskov
Session: Cocktail & Poster Display session
Resources:
Abstract